GLP-2(3-33 (Leu-13C6,15NN TFA「同位素标记抑制剂」
【产品介绍】:
生物活性:GLP-2(3-33) (Leu-13C6,15N) TFA is 13C and 15N labeled GLP-2(3-33) (HY-P2625). GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM).
体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
GLP-2(3-33) (Leu-13C6,15NN) TFA 相关抗体:
Glucagon Antibody
gamma Sarcoglycan Antibody (YA1357)
delta Sarcoglycan Antibody (YA3326)
分子量:3564.84 (free acid)
Formula:C15013C6H242N3915NO53S.xC2HF3O2
非标记 CAS:275801-62-2
Sequence
Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-{Leu-13C6,15N}-Ile-Gln-Thr-Lys-Ile-Thr-Asp
Sequence Shortening
DGSFSDEMNTI-{Leu-13C6,15N}-DNLAARDFINWLIQTKITD
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (529 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
[Content Brief]
[2]. Baldassano S, et al. Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet. Endocr Res. 2016 Nov;41(4):317-324.
[Content Brief]
[3]. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Ørskov C, Holst JJ, Poulsen SS. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept. 2002 Jan 15;103(1):9-15.
[Content Brief]